ERBB2 and breast cancer: Triple-negative breast cancer (TNBC), defined histologically as estrogen receptor negative, progesterone receptor negative and absence of HER2/neu amplification, represents 15–20% of all breast cancers and is characterized by an aggressive clinical course compared with other subtypes.